Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ibnsina PharmaCAI:ISPH -0.26%85 Days Payable is 129.21 as of Mar. 2026, which is 12% above its 10-year median of 115.42. GuruFocus rates CAI:ISPH with a GF Score™ of 85/100 and a GF Value™ of E£10.52 (Fairly Valued). The stock has 7 warning signs investors should review. Among 115 Medical Distribution companies, Ibnsina Pharma ranks better than 78.26% on this metric.
The historical rank and industry rank for Ibnsina Pharma's Days Payable or its related term are showing as below:
CAI:ISPH'
s Days Payable Range Over the Past 10 Years
Min: 112.12 Med: 115.42 Max: 131.75
Current: 118.77
During the past 10 years, Ibnsina Pharma's highest Days Payable was 131.75. The lowest was 112.12. And the median was 115.42.
CAI:ISPH's Days Payable is ranked better than 78.26% of 115
companies
in the Medical Distribution industry
Industry Median: 79.11
vs CAI:ISPH: 118.77
Ibnsina Pharma's Days Payable
increased
from Mar. 2025 (120.68) to Mar. 2026 (129.21).
It may suggest that Ibnsina Pharmadelayed paying its suppliers.
Ibnsina Pharma Days Payable Related Terms
Ibnsina Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for Ibnsina Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:ISPH vs MCK, CAH, COR: Days Payable Comparison
For the Medical Distribution subindustry, Ibnsina Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ibnsina Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ibnsina Pharma (CAI:ISPH) has a Days Payable of 129.21 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ibnsina Pharma and its competitors. This is 12% above median its historical median of 115.42. Over the past decade, Ibnsina Pharma's Days Payable has ranged from 112.12 to 131.75. According to the industry distribution chart, Ibnsina Pharma ranks #25 out of 115 companies in the Medical Distribution industry, placing it in the top 21.7%.
Is Ibnsina Pharma's Days Payable too high?
Ibnsina Pharma's current Days Payable of 129.21 is 12% above median its 10-year median of 115.42. Over the past 10 years, this metric has ranged from a low of 112.12 to a high of 131.75. The Medical Distribution industry median Days Payable is 79.11. Ibnsina Pharma's value of 129.21 is 63.3% above this industry median. Based on the distribution chart, Ibnsina Pharma ranks #25 out of 115 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Ibnsina Pharma has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Days Payable compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #25 out of 115 companies for Days Payable. This places Ibnsina Pharma in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 79.11. Ibnsina Pharma's value of 129.21 is 63.3% above this benchmark. Historically, Ibnsina Pharma's own Days Payable has ranged from 112.12 to 131.75 over the past decade. While the company's 10-year median is 115.42 vs. the industry median of 79.11, Ibnsina Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.11, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current Days Payable of 129.21 is 63.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median Days Payable is 79.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current Days Payable is 129.21, which is 12% above median its own 10-year median of 115.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Fairly Valued. The stock's GF Value™ is E£10.52, compared to a current price of E£11.47 — trading 9% above its estimated fair value. The current Days Payable is 129.21, which is 12% above median its 10-year median of 115.42 and 63.3% above the Medical Distribution industry median of 79.11. Ibnsina Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Days Payable is 129.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£11.47 is trading 9% above its estimated GF Value™ of E£10.52.
GuruFocus considers Ibnsina Pharma to be Fairly Valued.
Key valuation signals for CAI:ISPH:
Days Payable: 129.21 (12% above median its 10-year median of 115.42)
GF Value™: E£10.52 vs. price of E£11.47 (9% above fair value)
Industry Position: 63.3% above the Medical Distribution median (#25 of 115)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
85GF Score
Get the complete analysis for CAI:ISPH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
